Don't miss the opportunity
Barcelona – April 2019. Tractivus is about to close the financing round... Read more
Avoiding bacterial colonization on medical devices
Tractivus has a new Board of Directors
Barcelona – February 2020. Following the direction set by the Company and with the aim of professionalizing the management of Tractivus, on January 23rd an Extraordinary General Meeting of Shareholders was held with the aim of modifying the Company's administration regime so from now on it becomes governed and administered by a Board of Directors.
The Board of Directors is the body in charge of the government, direction and administration of the Company's business and interests in all that is not reserved to the General Shareholders' Meeting. It concentrates its activity in the general supervisory function and in the consideration of those matters of special importance for Tractivus.
​
Tractivus' highest body adapts to the new shareholding structure
​
​
Board of Directors
Joan Gilabert
He was graduated in Chemistry by Universitat Ramon Llull (Institut Químic de Sarrià), where he also obtained his Ph.D. in Bioengineering, focusing on the functionalization of bioactive surfaces. He also extended his field of research to additive manufacturing of personalized biomedical devices. He published 4 articles in international journals and is co-author of 4 patents. He has more than 4 years of experience leading a spin-off and co-founded Tractivus where helped to raise more than 1 million euros in public and private funds.
Salvador Borrós
Dr. Chemical Engineer from IQS, Master in Industrial Business Management and Diploma in Materials characterization. Director of the Materials Engineering Group (GEMAT) of the IQS, Universitat Ramon Llull (URL), and Professor of Materials and Biomaterials at URL. GEMAT is a consolidated research group recognised by AGAUR (Generalitat de Catalunya) and "Centro TECNIO", recognized by ACCIÓ (Generalitat de Catalunya). Its activity has focused for more than 20 years on the development of functional materials. Since 2000 he has led a recognized line of research in the field of biomaterials and the development of nanometric systems for drug release. He has published more than 120 articles in international journals (peer review) and has directed or co-directed 21 doctoral theses and more than 100 master's theses and final degree projects. Dr. Borrós has extensive experience participating in competitive projects, having been the IQS principal investigator in 5 National Plan Projects, 7 European Projects and others with business participation such as Innpacto, Challenges and collaboration and similars.
Dr. Borrós has a clear vocation for technology transfer, being the principal investigator of more than 50 industrial projects lasting more than a year and is the founder or co-founder of 7 spin-offs, based on technologies developed in his Group: khalkós , SL, Flubetech, SL, Sagetis-Biotech, SL, and Sailing Technologies, Tractivus SL and Aortyx, which have carried out successful rounds of financing.
Antoni Rosell
Pulmonologist and doctor of medicine, graduate in biostatistics and associate professor of master's degrees at the University of Barcelona (UB). He holds the position of Clinical Director of the Thorax Area at Hospital Germans Trias i Pujol and was previously the head of the Respiratory Endoscopy section of the Hospital Universitari de Bellvitge. He has been the introducer in Spain of endobronchial ultrasound, autofluorescence and the non-electromagnetic navigation system, and is an opinion leader in interventional bronchoscopy. He has been a researcher of the Pneumology group of IDIBELL and CIBER of respiratory diseases. European Certification of Pneumology (HERMES) in 2009. He has made short stays in international research and hospital centers (Amsderdam, Heidelberg, Lille and Vancouver). He participates as a reviewer of research projects of the Carlos III Institute, various public health agencies and international journals. He has published 15 articles in Q1. He is co-author of 3 patents, in collaboration with the Universtat Politècnica de Catalunya and the Institut Químic de Sarrià (IQS), as well as co-founder of the spin-off Adbroncus (2011). He has been the Principal Investigator of 5 competitive national projects in the last 10 years, in which he has counted as co-researchers biologists (PEBC-IDIBELL), engineers (UPC), mathematicians (CVC) and chemists (IQS). He is currently a co-researcher in a transfer project for the validation of an automated calculation system for real-time endoscopic images led by the Computer Vision Center (CVC-UAB).
Josep Lamarca
Independent consultant in the development of negotiations and licenses in the biopharmaceutical industry. He has worked at Laboratorios Rubió as a senior business development consultant and was a member of its Executive Committee. Previously, he worked at Laboratorios Almirall SA, Spain's leading pharmaceutical company as director of corporate / licensing development projects for several years since 1992. He had been reporting directly to GM and the company's CEO. Prior to this, he worked as a medical and scientific and regulatory affairs for Almirall. In addition, he worked as a neuropathologist for about 7 years at the Hospital Nuestra Señora de Mar in Barcelona
He highlights his experience in entry and exit licenses in the US. USA, Japan and Europe; interaction with pharmaceutical, biotech and pharmaceutical companies in these countries; alliance building; leadership of multidisciplinary teams in the association process; experience in supervising secondary quality agreements and preparing licensing strategies inside and outside the company.
Pau Corbera
He is a private investor in health and real estate companies and he also develops consultancy projects for Adequita. Adequita Capital Ltd, London, is a boutique advisory and venture building firm that brings together international expertise to deliver value creating projects. In the past, and focused in the Consumer Health market, Pau has successfully created product portfolios, entered and developed new international markets, building value companies through brands. He is an expert in Strategical Marketing and “Open Innovation” processes. Prior to Adequita, Corbera served as CEO of Laboratorios Diafarm more than 20 years, and at the same time he was an active member in several boards of directors in pharma companies, as Bioiberica and Impex Quimica. Before, he held executive positions at Procter & Gamble and PriceWaterhouse.